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Background: An increased risk of restrictive valvular heart disease (VHD) has been widely reported in patients
with Parkinson's disease (PD), as a possible consequence of the chronic use of ergot-derived dopamine agonists
(EDA), such as pergolide and cabergoline. An aspect that remains poorly investigated is the extent of reversibility
of the valvular dysfunction after drug discontinuation.
Methods: Fifteen patients with PD (8 male and 7 female) on chronic treatment with pergolide or cabergoline in
which a cardiacmono ormultivalvular ﬁbrosiswith orwithout regurgitationwas detected on echocardiographic
examination were enrolled in the study from March to December 2007. Because of this the EDA were
discontinued and replaced by a non-EDA or l-dopa. A second echocardiography has been performed after a
median duration of follow-up of 54 months in order to assess the course of valvular abnormalities i.e. regurgita-
tion, thickening of mitral valve anterior leaﬂet (MAL) and mitral valve tenting area.
Results: At the follow-up echocardiographic assessment a complete regression of MAL thickening in 7 out of 13
patients and of the aortic ﬁbrosis in 7 out 10 patients was observed. A statistically signiﬁcant improvement of
mitral and tricuspid valve regurgitation score, sum of regurgitations, thickening of MAL and mitral valve tenting
area was found. None of the patients showed a worsening of VHD after drug withdrawal.
Conclusions: This long-term study conﬁrms an improvement of the restrictive VHD afterwithdrawal of EDA in PD
patients. However, only a partial reversibility of cardiac valvular abnormalities was observed.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
An increased risk of regurgitant restrictive valvular heart disease
(VHD) has been widely reported in patients with Parkinson's disease
(PD) as a possible consequence of the chronic use of ergot-derived
dopamine agonists (EDA), such as pergolide and cabergoline [1]. This
adverse reaction is not a “class effect” [2], but seems to be related to spe-
ciﬁc pharmacodynamic properties of these agents, i.e. serotonin (5HT)
2B receptor agonist activity, which stimulates an abnormal proliferation
of valvular ﬁbroblasts and induces ﬁbrotic abnormalities in valve leaf-
lets and subvalvular apparatus, resulting in thickening, stiffening andogy Unit, Azienda Ospedaliero-
: +39 0521702070; fax: +39
eliability and freedom from bias
land Ltd. This is an open access articleretraction of valves and so eventually in valve regurgitation [3]. The
estimated prevalence of this restrictive VHD varies from 29% to 69%
for cabergoline and from 4% to 38% for pergolide [1], so that pergolide
has beenwithdrawn from theUSmarket [4], and in Europe theprescrip-
tion of pergolide and cabergoline is now restricted to a second-line
therapy for PD [5]. An aspect that remains poorly investigated is the
extent of reversibility of the valvular dysfunction after drug discontinu-
ation. To date, only a few studies [6–9] have been formally conducted to
assess this issue, reporting both a stability or a partial regression of
valvular abnormalities. Furthermore, there are no data about the long
term outcome of these valvulopathies, raising the doubt that the
above reported ﬁndings could be due to a too short drug-free period
of follow-up.
We have carried out a prospective longitudinal study to investi-
gate in PD patients the long term course of the cardiac valvular
dysfunctions after EDA discontinuation and their replacement with
non EDA or L-dopa.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2.1. Study design and patients
Fifteen out-patients with PD (8 male and 7 female), attending the
Movement Disorder Clinic at the Neurology Unit, Department of Neuro-
sciences, Azienda Ospedaliero-Universitaria of Parma, on pergolide or
cabergoline monotherapy for at least six months, were included in the
study from March to December 2007. The inclusion criteria were the
detection of cardiac uni or multivalvular ﬁbrosis, with or without
regurgitation, on an echocardiographic examination performed in the
course of treatment with EDA. Clinical exclusion criteria were a history
of congenital or rheumatic heart disease, dilated cardiomyopathy,
endocarditis or myocarditis, or coronary heart disease within 3 years
before the detection of valvulopathy, carcinoid syndrome, previous or
current use of anorectic drugs or other ergot alkaloid-derived drugs.
None of the patients has been assigned to class N2 of New York Heart
Association (NYHA) functional classiﬁcation [10]. Echocardiographic
exclusion criteria were valve calciﬁcation, valve regurgitation with
annular dilatation or excessive leaﬂet motion, mitral regurgitation
with abnormal left ventricular wall motion or left ventricular dilatation.
The patient's demographic and clinical features at the inclusion are
reported in Table 1. Because of the echocardiographic detection of
valvular ﬁbrosis the EDA treatment was discontinued and replaced
with non EDA (ropinirole in 7 patients and pramipexole in 5 patients)
or L-dopa (in 3 patients). The patients underwent a second echocardio-
graphic examination after a period varying from 34 to 60 months
(median duration of follow-up 54months) to assess the course of valvu-
lar abnormalities following EDA discontinuation.
2.2. Echocardiography
Transthoracic Doppler echocardiography was performed by using
the ultrasound system Vivid 5 (GE Medical Systems) in both pre
and post EDA discontinuation assessments. Echocardiographic and
Doppler data of patients were stored on optical disks for off-line anal-
ysis and were interpreted independently and in blinded fashion by
two expert sonographers (W.S. and D.O.). Valvular ﬁbrosis was con-
sidered to be present if hyperechogenic valve abnormalities were
echocardiographically detectable. Leaﬂet thickening was quantiﬁed
only for the mitral-valve anterior leaﬂet (MAL), with a pathological
value N0.5 cm. All semiquantitative and quantitative measurements
of regurgitant valve disease were made according to the standard
recommendations of the American Society of Echocardiography [11].Table 1
Demographic and clinical features of PD patients included in the study (N= 15).
Age (years)a 66.47 ± 10.11
Male/female (N) 8/7
Duration of PD (months)a 77.67 ± 51.24
Hohen & Yahr stageb 3 (2.5–4)
Pergolide (N of patients) 8
Cabergoline (N of patients) 7
Duration of therapy (months)a
Pergolide 76 ± 33.2
Cabergoline 26 ± 13.16
Cumulative dose (mg)a
Pergolide 4860.5 ± 2567.6
Cabergoline 1687.9 ± 1455.1
Mean daily dose (mg)a
Pergolide 2.09 ± 0.76
Cabergoline 2.11 ± 1.02




a Values are mean ± standard deviation.
b Value is median (range).Valve regurgitations were quantiﬁed as follows: absent, score 0;
trace, score 1; mild, score 2; and moderate to severe, score 3–4. If
one of the two readers differed from the other by one grade, the
higher rating was assigned. To evaluate the global risk of regurgitant
valve disease, we also used a composite scoring system (sum of
regurgitations) derived from the sum of mitral, aortic, and tricuspid
regurgitation scores (value range of the composite score 0 to 12;
higher scores indicate more severe dysfunction). As a quantitative
index of leaﬂet stiffening and apical displacement of mitral leaﬂet
coaptation, we have considered the mitral-valve tenting area, which
has been mainly used for mitral regurgitation in ischemic heart
disease [12]. As previously described [13], the mitral tenting area
was obtained from the parasternal long-axis view and measured as
the area enclosed between the annular plane and the mitral leaﬂets
at end systole (normal value b 3 cmq) (Fig. 1). Stiffening of the leaf-
lets and their displacement toward the apex cause an increase in this
area resulting in incomplete leaﬂet coaptation and ultimately in valve
regurgitation. To derive systolic pulmonary artery pressure (PAP), we
calculated the tricuspid-valve pressure gradient from the tricuspid
regurgitant jet velocity. We then increase the gradient by 5 mm Hg
if the diameter of the inferior vena cava was less than 10 mm with
complete respiratory collapse, by 15 mm Hg if the diameter of the
inferior vena cava was more than 20 mm without respiratory varia-
tion, and by 10 mm Hg in intermediate cases [13].
2.3. Statistical analysis
Values are given asmean±SD andmedian (range). The echocardio-
graphic parameters, before and after EDA discontinuation, were
compared intraindividually with a paired Student's t-test. The relation-
ship between improvement of each echocardiograﬁc parameter at the
follow-up assessment and age, gender, duration of EDA therapy, mean
daily and cumulative dose, duration of follow-up period and cardiovas-
cular risk factors was assessed with Pearson's correlation coefﬁcient.
Statistical analysis was carried out using IBM SPSS v20.0 (IBM, Armonk,
New York, USA). For all analyses we considered a value of p b 0.05 as
statistically signiﬁcant.
3. Results
Discontinuation of EDA therapy was associated with a complete
regression of MAL thickening in 7 out of 13 patients and of the aortic
ﬁbrosis in 7 out of 10 patients. At the end of follow-up the percentage
of the patients with mitral regurgitation (MR) decreased from 93% toFig. 1. “Mitral tenting area” (dotted triangle) detected in a patient from the parasternal
longitudinal axis andmeasured as the area enclosed between the annular plane andmitral
leaﬂets in systole. VS: left ventricle; AS: left atrium; AO: aortic root.
Table 2
Valvular abnormalities pre- and post-EDA discontinuation.
Echocardiographic parameter Pre-withdrawal
N of patients (%)
Follow-up
N of patients (%)
Mitral ﬁbrosis 13/15 (86.7) 6/15 (40)
Aortic ﬁbrosis 10/15 (66.7) 3/15 (20)
Tricuspid ﬁbrosis 0 0
Grade of mitral regurgitation
0 1 (6.7) 4 (26.6)
1 2 (13.3) 4 (26.6)
2 9 (60) 6 (40)
3–4 3 (20) 1 (6.7)
Grade of aortic regurgitation
0 8 (53.3) 12 (80)
1 3 (20) 0
2 3 (20) 2 (13.3)
3–4 1 (6.7) 1 (6.7)
Grade of tricuspid regurgitation
0 0 0
1 6 (40) 9 (60)
2 5 (33.3) 4 (26.6)
3–4 4 (26.6) 2 (13.3)
Thickening of mitral anterior leaﬂet 13/15 (86.7) 6/15 (40)
Regurgitation grades are as follows: 0, absent; 1, trace; 2, mild; 3–4, moderate to severe.
EDA: ergot-derived dopamine agonists.
Table 4
Restrictive VHD course after EDA discontinuation.
Echocardiographic parameter Pre-withdrawal Follow-up P-value
Mitral regurgitation grade 1.9 ± 0.76 1.23 ± 0.98 0.012
Aortic regurgitation grade 0.77 ± 0.98 0.43 ± 0.9 ns
Tricuspid regurgitation grade 1.87 ± 0.83 1.5 ± 0.68 0.01
Sum of regurgitations grade 4.53 ± 1.87 3.17 ± 1.88 0.001
Thickening of mitral anterior
leaﬂet (cm)
0.55 ± 0.06 0.44 ± 0.12 0.001
Mitral-valve tenting area (cm2) 2.89 ± 0.54 2.34 ± 0.72 0.018
Pulmonary artery pressure (mm Hg) 29.33 ± 5.14 32.9 ± 37.76 ns
Values are mean ± standard deviation. VHD: valvular heart disease; EDA: ergot-derived
dopamine agonists; ns: not signiﬁcant.
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signiﬁcant tricuspid regurgitation (TR) (grade N1) from 60 to 40%
(Table 2). Moreover the composite regurgitation score decreased in 12
patients out of 15 (80%), and in the other 3 patients remained
unchanged. The number of patients with regurgitant valves pre- and
post-EDA discontinuation is shown in Table 3. A statistically signiﬁcant
improvement of the following parameters was found: MR (p= 0.012)
and TR (p = 0.01), sum of regurgitations (p = 0.001), thickening of
MAL (p= 0.001), and mitral-valve tenting area (p= 0.018). No statis-
tically signiﬁcant change was observed for AR and PAP. However, the
mean value of PAP showed a trend toward an increase after EDA discon-
tinuation (Table 4). During the follow-up period no signiﬁcant change
in distribution and in severity of cardiovascular risk factors was found.
There was no relationship between the improvement of echocardio-
graphic parameters and age, gender, duration of EDA therapy, mean
daily and cumulative dose of EDA, cardiovascular risk factors and
duration of follow-up period.4. Discussion
To which extent restrictive VHD associated to the prolonged use of
the EDA pergolide and cabergoline in PD patients regresses after drug
discontinuation remains a still unresolved question. In the few follow-
up studies [6–9], aimed at the assessment of the clinical outcome of
VHD, an echocardiographic examination made on average 3 months to
about 22months after EDAwithdrawal showed a trend toward a partial
regression of VHD, but a complete resolution of the valvular functional
and/or morphological damage has not been found. These results are in
line with those previously reported with anorectic drugs, such as
fenﬂuramine and dexfenﬂuramine [14], which share the samemitogen-
ic effect on cardiac valvular ﬁbroblasts and smooth muscle cells,Table 3
Number of regurgitant valves pre- and post-EDA discontinuation.
Number of valves involved Pre-withdrawal
N of patients (%)
Follow-up
N of patients (%)
One valve 1 (6.8) 3 (20)
Two valves 7 (46.6) 10 (66.7)
Three valves 7 (46.6) 2 (13.3)
EDA: ergot-derived dopamine agonists.believed to be mediated by stimulation of the 5HT2B receptors family,
even though other factors might be involved [15]. Would this mean
that the possibility of recovery of previous structure and function of
the valve is only partial? Or could it simply be due to the fact that the
echocardiographic assessment has been made after a too short period
of drug discontinuation? Indeed, one of the limitations of these studies
is the relatively short follow-up after EDA suspension, which could
have caused an underestimation of the extent of regression of VHD.
Our study, although conducted on a small number of PD patients, is
the ﬁrst to investigate the outcome of VHD associated to EDA with a
follow-up duration on average more than double as compared to the
longest so far reported [8]. On the other hand, a long follow-up could
have some limitations. In fact it is well-known that aging and
atherosclerotic risk factors increase the risk of developing valvular re-
gurgitation [16] due to the occurrence of co-morbidities, which make
more difﬁcult to identify the true effect of the suspension of EDA on
the structure and function of cardiac valvular apparatus. However, al-
though we cannot completely eliminate this source of bias, during the
observation period changes in the number of patients with comorbidi-
ties for arterial hypertension, dyslipidemia and diabetes mellitus have
not been detected. In our patients at the follow-up assessment a statis-
tically signiﬁcant improvement of all echocardiographic parameters an-
alyzed has been found, except for AR and PAP. The results of our study
are in agreement with those by Dupuy et al. [6] who ﬁrst examined
the course of EDA-related valvular damage in a group of 10 PD patients
in which pergolide had been suspended for a median period of 13
months, reporting in 60% of them a signiﬁcant improvement of the mi-
tral valve regurgitation grading and of the sum of regurgitations grad-
ing, as well as of number of affected valves. Our ﬁndings on valvular
regurgitation differ from those published by Rasmussen et al. [7], who
didn't ﬁnd any signiﬁcant change in AR, MR and TR one year after EDA
discontinuation, whereas a worsening of these parameters was
observed in patients who continued taking the EDA. Zanettini et al.
observed a signiﬁcant decrease of composite regurgitation score, but
not of the single valve regurgitation score, in a cohort of 21 PD patients
with moderate to severe (grade 3 to 4) regurgitation 22 months on av-
erage after the cessation of cabergoline and pergolide [8], whereas in
our patients the improvement of the sum of regurgitations was associ-
ated to an amelioration of MR and TR. In our patients only AR showed
an evolution apparently independent from the withdrawal of EDA,
even though the aortic-valve was functionally less affected than themi-
tral and tricuspid valves. Therefore, it is possible that the persistence of
AR may be inﬂuenced by additional risk factors other than EDA drugs
[16], and/or that a “ﬂoor effect”, due to the mild involvement of this
valve, may explain the lack of recovery. A completely different course
of AR, i.e. improvement in 33% of the patients who discontinued
cabergoline, has been reported by Fietzek et al. in 6 PD patients after a
follow-up as short as 3 months on average, whereas the outcome of
MR and TR was independent of drug cessation [9]. The statistically
signiﬁcant improvement of thickening of MAL and mitral tenting area,
which are indicators of structural abnormalities typical of ergot-
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al provides indirect conﬁrmation that the valvular dysfunctions could be
induced by these drugs. In line with data available in the literature [7,8]
the improvement of both functional and structural valvular abnormali-
ties was found to be independent of the demographic, clinical and ther-
apeutic factors analyzed. In particular, neither the duration nor the daily
and cumulative dosage of EDA inﬂuenced the course of valvular damage
following drug suspension. On the other hand, a delayed regression of
the valvular ﬁbrotic reaction, so resulting in a lack of its complete recov-
ery even on the long-term, could be ascribed to the switch to ropinirole
and pramipexole in most of the patients. However, this hypothesis
seems unlikely since as yet there is no evidence derived from clinical
[17] and experimental [18] studies, suggesting that the non EDA are as-
sociated with an increased risk or incidence of restrictive VHD.
In our patients the values of PAP showed a not signiﬁcant increase
following the suspension of EDA. The PAP is a parameter signiﬁcantly
affected by the action of 5HT, which induces vasoconstriction and
proliferation of arteriolar smoothmuscle cells. In this process seroto-
nergic receptors, in particular 5HT1B which induce vasoconstriction
of pulmonary arteries [19], and 5HT 2B, whose expression increases
in pulmonary arteries in patients with pulmonary hypertension,
seem to play a signiﬁcant role [20]. As yet, the effect of EDA on PAP
has been evaluated only by few authors [1,21,22], showing an
increased risk associated to prolonged exposure to pergolide. Also
the anorectic drugs have long been known to determine an increased
risk of pulmonary hypertension, which is reported to increase with
longer duration of therapy [23]. The only data on the course of PAP
after EDA discontinuation has been reported by Rasmussen et al.,
who found in PD patients a slight but signiﬁcant decrease of mean
values of PAP and a regression of previous pulmonary hypertension
in 3 patients [7]. In contrast to the ﬁndings of Rasmussen et al. [7],
in this study two female patients at the follow-up examination
after suspension of pergolide developed a pulmonary hypertension
(45 mm Hg and 51 mm Hg, respectively). The different outcome of
PAP and VHD in these patients could be due to the fact that the
former is inﬂuenced by other concurrent unknown factors, possibly
genetically determined.
5. Study limitations
Anumber of limitations apply to this study. First, the small size of the
cohort of PD patients examined. Second, only one follow-up echocardio-
graphic assessment in each patient has been made and the duration of
the follow-up was not standardized. Furthermore, none of the patients
had echocardiographic examination before starting EDA therapy, so
that a pre-existing subclinical VHD cannot be ruled out. Lastly, only
few patients had a severe valvular regurgitation, so that the results
cannot be extrapolated and considered to be representative of the entire
population of PD patients exposed to EDA.
6. Conclusions
In this long-lasting follow-up study after EDA discontinuation none
of the patients showed a complete regression of the valvular abnormal-
ities, thus conﬁrming previous reports of an only partial structural and
functional recovery of VHD. The ﬁnding of an interindividual different
outcome of VHD in PD patients could be due to the fact that other
concurrent unknown factors, in addition to the use of EDA, are involved
in the clinical course of this disease.
The ﬁnding of an only partial reversibility of pergolide and
cabergoline-associated VHD on the long-term makes no more suitable
a chronic treatment of PD with these drugs as a ﬁrst line therapy,
corroborating the decision taken to this regard by the Drug Regulatory
Agencies in Europe and United States. However, for research purposethe results of this study should be conﬁrmed on larger cohort of PD
patients with a comparable long duration of follow-up and with serial
echocardiographic assessments.
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